Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 8
2020 9
2021 7
2022 8
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution.
Gutkind JS, Faraji F, Ramirez S, Clubb L, Sato K, Quiroz PA, Galloway W, Mikulski Z, Hoang T, Medetgul-Ernar K, Marangoni P, Jones K, Officer A, Molinolo A, Kim K, Sakaguchi K, Califano J, Smith Q, Klein O, Tamayo P. Gutkind JS, et al. Res Sq [Preprint]. 2023 Oct 27:rs.3.rs-3426301. doi: 10.21203/rs.3.rs-3426301/v1. Res Sq. 2023. PMID: 37961717 Free PMC article. Preprint.
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, Patel HV, Koshizuka K, Soifer HS, Kessler L, Dayoub A, Villaflor V, Adkins DR, Bruce JY, Ho AL, Perez CA, Hanna GJ, Gascó Hernández A, Saunders A, Dale S, Gutkind JS, Burrows F, Malik S. Smith AE, et al. Cancer Res. 2023 Oct 2;83(19):3252-3263. doi: 10.1158/0008-5472.CAN-23-0282. Cancer Res. 2023. PMID: 37339176 Free PMC article.
The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.
Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS. Wu VH, et al. Nat Immunol. 2023 Aug;24(8):1318-1330. doi: 10.1038/s41590-023-01529-7. Epub 2023 Jun 12. Nat Immunol. 2023. PMID: 37308665 Free PMC article.
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Jagadeeshan S, Prasad M, Badarni M, Ben-Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, Friedmann-Morvinski D, Cheong SC, Ho AL, Rosenberg AJ, Kessler L, Burrows F, Kong D, Grandis JR, Gutkind JS, Elkabets M. Jagadeeshan S, et al. Cancer Res. 2023 Apr 4;83(7):1031-1047. doi: 10.1158/0008-5472.CAN-22-2586. Cancer Res. 2023. PMID: 36753744 Free PMC article.
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
Nathan CO, Hayes DN, Karrison T, Harismendy O, Flores JM, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEW. Nathan CO, et al. Clin Cancer Res. 2022 Dec 1;28(23):5040-5048. doi: 10.1158/1078-0432.CCR-21-4290. Clin Cancer Res. 2022. PMID: 36194164 Free PMC article. Clinical Trial.
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer.
Saddawi-Konefka R, Schokrpur S, Lui AJ, Gutkind JS. Saddawi-Konefka R, et al. Cancer J. 2022 Sep-Oct 01;28(5):339-345. doi: 10.1097/PPO.0000000000000622. Cancer J. 2022. PMID: 36165721 Free PMC article. Review.
40 results